BTAI
BioXcel Therapeutics Inc
NASDAQ: BTAI · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.04
-1.89% today
Updated 2026-04-29
Market cap
$28.70M
P/E ratio
—
P/S ratio
44.70x
EPS (TTM)
$-5.73
Dividend yield
—
52W range
$1 – $8
Volume
1.8M
WallStSmart proprietary scores
14
out of 100
Grade: F
Strong Sell
Investment rating
4.7
Growth
C5.0
Quality
C+2.5
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$14.00
+1246.15%
12-Month target
—
—
Intrinsic (DCF)
$2.60
Margin of safety
+37.69%
0 Strong Buy3 Buy0 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 37.69% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-14.21M
- Revenue declining -30.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $375000.00 | $1.38M | $2.27M | $642000.00 | $642000.00 |
| Net income | $-165.76M | $-179.05M | $-59.60M | $-69.90M | $-12.54M |
| EPS | — | — | — | — | $-5.73 |
| Free cash flow | $-135.48M | $-155.03M | $-72.03M | $-57.62M | $-14.21M |
| Profit margin | -44,201.87% | -12,974.86% | -2,630.14% | -10,887.38% | — |
Peer comparison
Smart narrative
BioXcel Therapeutics Inc trades at $1.04. Our Smart Value Score of 14/100 indicates the stock is weak. TTM revenue stands at $642000.00. Our DCF model estimates intrinsic value at $2.60.
Frequently asked questions
What is BioXcel Therapeutics Inc's stock price?
BioXcel Therapeutics Inc (BTAI) trades at $1.04.
Is BioXcel Therapeutics Inc overvalued?
Smart Value Score 14/100 (Grade F, Strong Sell). DCF value $2.60.
What is the price target of BioXcel Therapeutics Inc (BTAI)?
The analyst target price is $14.00, representing +1246.2% upside from the current price of $1.04.
What is the intrinsic value of BioXcel Therapeutics Inc (BTAI)?
Based on our DCF model, intrinsic value is $2.60, a +37.7% margin of safety versus $1.04.
What is BioXcel Therapeutics Inc's revenue?
TTM revenue is $642000.00.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio44.70x
ROE-1,767.00%
Beta0.30
50D MA$1.40
200D MA$2.21
Shares out0.03B
Float0.02B
Short ratio—
Avg volume1.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—